ClinicalTrials.gg

Program

JK07

A development code.

Its studies are mostly in Heart Failure, led by Shenzhen Salubris Pharmaceuticals.

Furthest: phase 2, since Apr 12, 20244 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shenzhen Salubris Pharmaceuticals41 open or runningphase 2since Apr 12, 2024Dec 17, 2019none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 17, 2019First study: phase 1 study in Heart FailureFirst studyNCT04210375 · 14 enrolled · United States
  2. Mar 14, 2022Phase 1 study in Heart FailureNCT05322616 · United States
  3. Apr 12, 2024Phase 2 study in Heart FailureNCT06369298 · 282 enrolled · United States, Canada, China and more
  4. Aug 20, 2025Phase 2 study in Heart FailureNCT07221513 · United States

TargetBeta

EGF →read by rule
“JK07 is a fully human anti-human epidermal growth factor receptor 3 (also known as ErbB3 or HER3) antibody fused with the epidermal growth factor (EGF)-domain of Neuregulin (NRG)-1b protein.”study text, by rule · the study

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07221513Heart Failure · United States2WithdrawnApr 16, 20260
NCT06369298Heart Failure · United States, Canada, China and more2Active, not recruitingOct 31, 2026282
NCT05322616Heart Failure · United States1WithdrawnMay 26, 20230
NCT04210375Heart Failure · United States1CompletedJun 8, 202314

How it is read

Names in the registry

  • “JK07”, 4 entries

Codes read as this program: JK07.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.